External trigeminal nerve stimulation (eTNS) may be an effective and well-tolerated rescue therapy for acute vestibular migraine (VM) attacks, a small retrospective study suggests. For 19 patients in ...

Highlighting the latest migraine-related news reported across MJH Life Sciences™. But those who suffer from the condition may be labeled as attention-seeking or have their attacks downplayed as just a ...

KT Corp. took its first step into the digital therapies space by entering into an agreement with Neurosigma Inc. to develop electronic therapies to treat neurological and neuropsychological disorders, ...

Explore how external trigeminal nerve stimulation offers hope for veterans battling PTSD and MDD in a groundbreaking study. Ron Ramirez, a retired Army sergeant is participating in the second phase ...

CHICAGO ― Trigeminal nerve stimulation (TNS) is safe and effective in alleviating symptoms of attention-deficit/hyperactivity disorder (ADHD) in children, a new ...

Virtual reality systems are getting better and better all the time, but they remain largely ocular and auditory devices, with perhaps a little haptic feedback added in for good measure. That still ...

But in April, the FDA approved the first device-based, non-drug therapy to treat ADHD in children. The FDA decision followed the completion of a UCLA study demonstrating the effectiveness and safety ...

PHILADELPHIA & NETANYA, Israel--(BUSINESS WIRE)--Neurolief, a developer of next-generation digital therapeutics brain neuromodulation technology, today announced that findings of a clinical study ...

LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating ...

The Food and Drug Administration has approved the first device designed to treat Attention Deficit Hyperactivity Disorder (ADHD) in children. The device is only available as a prescription, offering ...